Mineral trioxide aggregate and formocresol pulpotomy of primary teeth: a 2-year follow-up.
OBJECTIVE
To compare the clinical and radiographic response of primary teeth to vital pulpotomy using mineral trioxide aggregate (MTA) or formocresol (FC).


METHODS
A group of 17 children aged 4-9 were selected from those referred to the Paedodontic Department at Shahid Beheshti University, Dental School. Cases with at least two matching teeth were selected (40 teeth), showing signs of pulp involvement. A pulpotomy procedure was carried out in all cases with FC in control teeth whilst MTA was placed in experimental teeth. Clinical and radiographic evaluations were performed at 1-, 6-, 12- and 24-month recall. Statistical analysis using a Fischer exact test was performed on the data to determine significant differences between the groups.


RESULTS
Overall, 22 second and 18 first primary molars were included. The gender ratio was one male to three female. No significant difference was found between the clinical and radiographic outcomes of the two groups at 6-, 12- and 24-month follow-up (P > 0.05). Internal resorption was seen significantly more often in FC cases after 12 months than MTA cases. Overall radiographic appearance of normal structures at 24th month was seen in more than 95% of the cases in MTA and 90% in the FC-treated group (P > 0.05).


CONCLUSIONS
Mineral trioxide aggregate for pulp treatment of primary teeth can be considered a replacement for FC.
Deptartment of Paedodontics, Dental School, Shahid Beheshti University of Medical Sciences, Tehran, Iran. bujdent@yahoo.co.uk
G
G
Ansari
M
M
Ranjpour
D017607:Aluminum Compounds / Q000627:therapeutic use*; D017610:Calcium Compounds / Q000627:therapeutic use*; D016022:Case-Control Studies; D002648:Child; D002675:Child, Preschool; D003442:Crowns; D003723:Dental Amalgam; D003731:Dental Caries / Q000628:therapy; D003782:Dental Pulp / Q000187:drug effects; D003793:Dental Restoration, Permanent; D003794:Dental Restoration, Temporary; D004338:Drug Combinations; D005260:Female; D005500:Follow-Up Studies; D005566:Formocresols / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008963:Molar / Q000000981:diagnostic imaging / Q000473:pathology; D010087:Oxides / Q000627:therapeutic use*; D010513:Periodontal Ligament / Q000000981:diagnostic imaging; D011672:Pulpotomy / Q000379:methods*; D016300:Radiography, Bitewing; D017640:Silicates / Q000627:therapeutic use*; D014091:Tooth Resorption / Q000000981:diagnostic imaging / Q000209:etiology; D014094:Tooth, Deciduous / Q000000981:diagnostic imaging / Q000473:pathology*; D016896:Treatment Outcome; D015035:Zinc Oxide-Eugenol Cement
D017607:Aluminum Compounds; D017610:Calcium Compounds; D004338:Drug Combinations; D005566:Formocresols; D010087:Oxides; D017640:Silicates; D015035:Zinc Oxide-Eugenol Cement; C086631:mineral trioxide aggregate; C031025:formocresol; D003723:Dental Amalgam